US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.16 against a street estimate of 0.10 — a beat of 60.0%.
Analysts rate Azenta Inc a buy (3 buy, 3 hold, 0 sell out of 6) with an average price target of $37.80.
| Fund | Stake |
|---|---|
| BlackRock Inc | 17.19% |
| Politan Capital Management LP | 10.55% |
| Vanguard Portfolio Management, LLC | 5.69% |
| Vanguard Capital Management, LLC | 4.27% |
| State Street Corp | 4.25% |
| Massachusetts Financial Services Company | 3.25% |
| D. E. Shaw & Co LP | 3.06% |
| Morgan Stanley - Brokerage Accounts | 3.04% |
| Document | Date |
|---|---|
| Material agreement · Q1 FY2027 HEADLINE NUMBERS • Azenta entered into agreements with Elegen Corp. on October 28, 2026, covering an exclusive gene-synthesis technology license and | 2026-10-30 |
| Current report · Q1 FY2027 HEADLINE NUMBERS • Azenta approved a restructuring plan in its Multiomics segment on October 5, 2026. • Estimated pre-tax charges: approximately $11 | 2026-10-07 |
| Board / officer change · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY (SEPTEMBER 11, 2026) HEADLINE NUMBERS • Interim CEO base salary: $600,000 annually • Interim CEO cash performance bo | 2026-09-17 |
| Reg FD disclosure · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received full USD 63,000,000 purchase price for B Medical Systems sale in cash on Septemb | 2026-09-04 |
| Board / officer change · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size reduced from 9 to 8 members following leadership change on August 22, 2026 • No financ | 2026-08-24 |
| Board / officer change · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New executive appointment effective August 31, 2026: Erik J. Bello joins as Vice President, Chief | 2026-08-11 |
| Quarterly report · Q3 FY2026 AZENTA, INC. — Q3 2026 (ENDED JUNE 30, 2026) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Total Revenue (9 months): $454.6 million vs. $434. | 2026-08-06 |
| Results announced · Q4 FY2026 AZENTA Q3 FISCAL 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q3 revenue from continuing operations: $161 million, up 12% year-over-year • Q3 organic rev | 2026-08-04 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive gene synthesis technology license and supply agreement with Elegen Azenta entered two related agreements with Elegen and separately acquired all of SynPlexity, a DNA-assembly technology company. The Elegen deal gives Azenta an exclusive, royalty-free worldw | 2026-10-30 |
| Subsidiary provides $35M vendor loan to facilitate B Medical Systems acquisition Azenta completed the sale of B Medical Systems on July 1, 2026, for $63 million. The buyer, Thelema S.à r.l., paid $28 million in cash and received a $35 million vendor loan (financing provi | 2026-07-08 |
| Completes strategic acquisition of UK Biocentre Limited to expand biorepository capabilities Azenta completed its acquisition of UK Biocentre Limited for £20.5 million (plus up to £1.8 million in contingent payments), a UK-based provider of sample management, storage, and processing | 2026-03-04 |
| Sale and purchase agreement for entire issued share capital of B Medical Systems Azenta, Inc. has agreed to sell its entire stake in B Medical Systems S.à r.l. to Thelema S.à r.l., a Luxembourg-based company, through its German subsidiary Azenta Germany GmbH. The transac | 2025-12-29 |
| Board approves $250 million share repurchase program through 2028 Azenta's Board of Directors authorized a $250 million share repurchase program, effective December 9, 2025, through December 31, 2028. The company can buy back its own stock through open mar | 2025-12-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Azenta Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.